{"id":231224,"title":"Summary: NACI update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants, CCDR 48(7/8) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T19:08:03.327000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-statement-update-recommended-use-palivizumab-reduce-complications-respiratory-syncytial-virus-infection-infants.html?wbdisable=false","snippet":"Summary: NACI update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants, CCDR 48(7/8) - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement du Canada Search Search…","rawSnapshotUrl":"/api/snapshots/raw/231224","browseUrl":"https://replay.healtharchive.ca/job-1/20250418190803/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-statement-update-recommended-use-palivizumab-reduce-complications-respiratory-syncytial-virus-infection-infants.html?wbdisable=false#ha_snapshot=231224","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}